Truist on Verona Pharma (VRNA): 'We Continue to See a Potential Blockbuster in Ohtuvayre'
Tweet Send to a Friend
Truist Securities analyst Joon Lee reiterated a Buy rating and $100.00 price target on Verona Pharma (NASDAQ: VRNA).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
